摘要
动脉硬化闭塞症(ASO)是由动脉粥样硬化(AS)导致的肢体慢性缺血性疾病,该病严重影响着患者的生活质量,是血管性截肢的主要病因,重者甚至危及生命,其发病率也逐年上升。血同型半胱氨酸(Hcy)是已经被证实了的ASO的独立风险因素,在ASO的诸多风险因素中,高同型半胱氨酸血症(HHcy)作为近年热门研究的可干预因素,越来越受到重视。使用叶酸(FA)和维生素B12(VB12)干预能显著降低血Hcy水平,但干预的意义存在很大争论,能否开发新的干预途径值得研究,该文就HH-cy在ASO发病中所起的作用及其干预措施研究进展进行综述。
Atherosclerosic obliterans（ASO） is a chronic low limbs ischemic disease cauesed by atherosclerosis（ AS）, which seriously af- fects the patient＇ s quality of life, and is the main cause of vascular amputation, even endanger people＇ s lives, Its incidence has increased year by year. Circulating homotsteine （Hcy）is an independent risk factor of ASO, among which hyperhomocysteine（HHcy） as an interven- tion factor being investigated in recent years, holds more and more attention. Intervention with folic acid（ FA ）and vitamin B12 （VB12）can significantly decrease Hcy levels, however there are debates about the outcome of intervention. Further study is needed in how to develop new intervention approaches. This review is about the role of HHcy in ASO, and its intervention measures.
出处
《安徽医药》
CAS
2013年第4期688-690,共3页
Anhui Medical and Pharmaceutical Journal
关键词
动脉硬化闭塞症
同型半胱氨酸
相关性
干预
arteriosclerosis obliterans
homocysteine
relationship
intervention
